PD-1抑制剂治疗与急性肾损伤及低钙血症相关:荟萃分析
结果显示,与非肾毒性对照相比,PD-1抑制剂显著增加急性肾损伤风险(RR 4.19, 95%CI 1.57-11.18),并与低钙血症显著相关(RR 10.87, 95%CI 1.40-84.16)。AKI和低钙血症的合并发生率分别为2.2%和1.0%,AKI患者中间质性肾炎发生率为16.6%。
要点
- PD-1抑制剂较非肾毒性药物显著增加急性肾损伤风险(RR 4.19)。
- PD-1抑制剂与低钙血症风险显著相关(RR 10.87)。
- 建议PD-1抑制剂治疗期间除电解质外常规监测血钙。
核心结论
- PD-1抑制剂治疗与非肾毒性药物相比急性肾损伤风险更高。
- PD-1抑制剂治疗与低钙血症风险增加相关。
研究设计与样本
- 检索MEDLINE、EMBASE和Cochrane数据库至2017年4月,方案注册号CRD42017060579。
主要发现
- 所有急性肾损伤的合并风险比为1.86(95%CI 0.95-3.64)。
- 所有电解质异常的合并风险比为1.67(95%CI 0.89-3.12)。
- 与非肾毒性对照相比,急性肾损伤的合并风险比为4.19(95%CI 1.57-11.18)。
- 预设亚组分析显示PD-1抑制剂与低钙血症显著相关,合并风险比为10.87(95%CI 1.40-84.16)。
- 急性肾损伤和低钙血症的合并估计发生率分别为2.2%(95%CI 1.5-3.0%)和1.0%(95%CI 0.6-1.8%)。
临床怎么用
- 使用PD-1抑制剂时应常规监测血钙,并完善电解质 panel。
- 对PD-1抑制剂治疗期间发生急性肾损伤的患者,应评估间质性肾炎可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The aim of this meta-analysis was to assess the risks and incidence of nephrotoxicity and electrolyte abnormalities in patients receiving programmed cell death protein 1 (PD-1) inhibitors. METHODS: We conducted a meta-analysis of clinical trials that monitored electrolyte levels and kidney functions during treatment with nivolumab or pembrolizumab by searching MEDLINE, EMBASE and the Cochrane Database from inception through April 2017. Our protocol is registered with International Prospective Register of Systematic Reviews; no.CRD42017060579. RESULTS: A total of 48 clinical trials with a total of 11 482 patients were included. The overall pooled risk ratios (RR) of all acute kidney injury (AKI) and all electrolyte abnormalities in patients treated with PD-1 inhibitors were 1.86 [95% confidence interval (CI) 0.95-3.64] and 1.67 (95% CI 0.89-3.12), respectively. Compared with non-nephrotoxic controls, the pooled RR of AKI in patients treated with PD-1 inhibitors was 4.19 (95% CI 1.57-11.18). Prespecified subgroup analyses demonstrated a significant association between PD-1 inhibitors and hypocalcemia with a pooled RR of 10.87 (95% CI 1.40-84.16). The pooled estimated incidence rates of AKI and hypocalcemia in patients treated with PD-1 inhibitors were 2.2% (95% CI 1.5-3.0%) and 1.0% (95% CI 0.6-1.8%), respectively. Among patients who developed AKI with PD-1 inhibitors, the pooled estimated rate of interstitial nephritis was 16.6% (95% CI 10.2-26.0%). CONCLUSIONS: Treatment with PD-1 inhibitors is associated with a higher risk of AKI compared with non-nephrotoxic agents. It will be important to characterize the AKI patients to better understand the etiology behind the event. In addition, treatment with PD-1 inhibitors is associated with an increased risk of hypocalcemia. This study highlights a rare but serious adverse event of anti-PD-1 antibodies and we recommend, in addition to electrolytes panel, routine calcium monitoring.
引用
- Manohar S, Kompotiatis P, Thongprayoon C, et al. Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis. Nephrol Dial Transplant. 2019. PMID: 29762725. doi:10.1093/ndt/gfy105
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。